



Chairman of the Board
Bernard P. Dennis

President
Elliott M. Antman, MD, FAHA

Chairman-elect
Alvin L. Royse, JD, CPA

President-elect
Mark A. Creager, MD, FAHA

Immediate Past
Chairman of the Board
Ron W. Haddock

Immediate Past President
Mariell Jessup, MD, FAHA

Treasurer
David A. Bush

Directors
Mary Ann Bauman, MD
Mary Cushman, MD, MSc, FAHA
Mitchell S. V. Elkind, MD, MS, FAHA
Robert A. Harrington, MD
Steven R. Houser, PhD, FAHA
Marsha Jones
Willie E. Lawrence, Jr., MD, FAHA
Pegui Mariduena, CMC, MBA
John J. Mullenholz
Bertram L. Scott
David A. Spina
Bernard J. Tyson
Raymond P. Vara, Jr.
John J. Warner, MD
Alexander P. Almazan, PA - Liaison
James J. Postl - Liaison

Chief Executive Officer
Nancy A. Brown

Chief Mission Officer
Meighan Girgus

Chief Diversity Officer
Gerald Johnson, II

Chief Administrative Officer &
Chief Financial Officer
Sunder D. Joshi

Chief Science & Medical Officer
Rose Marie Robertson, MD, FAHA

Chief Development Officer
Suzie Upton

Chief of Staff to the CEO
Laura Sol

Deputy Chief Medical Officer
Eduardo Sanchez, MD, MPH

Executive Vice President,
Corporate Secretary &
General Counsel
Lynne M. Darrouzet, Esq.

Advocacy Department

1150 Connecticut Ave., NW | Suite 300 | Washington, DC 20036
P 202-785-7900 | F 202-785-7950 | www.heart.org

April 27, 2015

The Honorable Jim Cooper
U.S. House of Representatives
Washington, DC 20515

Dear Representative Cooper:

On behalf of the American Heart Association/American Stroke Association, we are pleased to support the Research for All Act.

The AHA/ASA has long recognized the need to increase diversity in research. Without such diversity, many questions about how and why cardiovascular disease (CVD) manifests differently in women and men remain unanswered. We support efforts to improve the representation of women and other under-represented groups in clinical trials so that potential differences in how treatments work can be discovered before these products are widely used in patients.

The cardiovascular field contains numerous examples of drugs and medical devices working differently in women or other subgroups. To give just a few examples, the drug digoxin used to treat patients with heart failure is associated with an increased risk of death among women but not men, and a next-generation ventricular assist device, used in heart failure patients, was associated with a higher rate of stroke in women versus men.

Your legislation will help to further our understanding of the sex differences that exist in the area of CVD. The National Institutes of Health's (NIH) development of guidelines on the inclusion of female cells, tissues, and animals in basic research and gender reporting in pre-clinical studies will ultimately lead to a better understanding of the biological reasons why CVD manifests differently in women and men. In addition, by directing the NIH to update its guidelines to better enforce the current law on inclusion of women in clinical research, authorizing funding for NIH's Special Centers of Research on Sex Differences, and directing the Government Accountability Office to update its reports on the inclusion of women in clinical trials, we can help ensure that women are being adequately and appropriately included in medical research.

Greater diversity in research is important for all Americans so that we can one day fulfill the promise of personalized medicine. Thank you again for your leadership on this issue.

Sincerely,

Elliott M. Antman, MD, FAHA
President

*"Building healthier lives, free of
cardiovascular diseases and stroke."*

life is why™ es por la vida™ 全为生命™